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(Krumholz et al., 2007). When the truth
of the real risks emerged, the drug was
withdrawn. Systematic reviews serve to
foster such enlightenment.
We agree with Rees’ description of
P-values as indicating false positive
error rates when used in the context of
elementary frequentist statistical theory.
We still maintain, however, that one of
the advantages of systematic reviews is
that they can improve the precision of
estimates derived from smaller similar
trials, thus making lots of additional
trials unnecessary when an acceptable
level of false positive error has been
reached. To date, 14 placebo-con-
trolled trials of topical pimecrolimus
for atopic eczema have been con-
ducted – do we really need any more
to convince the clinical community that
pimecrolimus is effective when com-
pared to vehicle? A more serious
example is the use of intravenous
streptokinase as thrombotic therapy for
myocardial infarction. By performing a
cumulative meta-analysis of similar
RCTs, Lau et al., (1992) showed clear
and consistent benefit for streptokinase
after just eight RCTs involving 2,432
patients had been performed in 1973.
Yet by 1988, a further 25 RCTs invol-
ving another 35,542 patients had been
performed in isolation addressing the
same question without altering the
risk estimate, but making the overall
P-value very small indeed (Po0.0001).
Such an observation illustrates the hu-
man cost of failing to observe the need
to bring all evidence together within the
body of a systematic reviews, as op-
posed to wasting valuable patient and
doctor resources in continuing to per-
form one inconclusive trial after an-
other. There comes a point when the
likelihood of a false positive results
becomes very remote, and even
the most skeptical person would say
‘‘enough is enough’’.
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TO THE EDITOR
Non-bullous congenital ichthyosiform
erythroderma (NBCIE; OMIM 242100)
is a rare, autosomal recessive disorder
characterized by prominent erythroder-
ma and fine, white, superficial scales.
Mutations in the transglutaminase 1
gene (Laiho et al., 1997; Akiyama
et al., 2001; Becker et al., 2003), the
12R-lipoxygenase gene, the lipoxygen-
ase-3 gene (Jobard et al., 2002), ichthyin
(Lefe`vre et al., 2004), and FLJ39501
(Lefe`vre et al., 2006) have been identi-
fied as causal in human NBCIE.
Recently, mutations in the gene en-
coding the adenosine triphosphate-bind-
ing cassette transporter protein ABCA12
(OMIM 607800) have been reported
to cause type II lamellar ichthyosis (LI;
OMIM 601277) (Lefe`vre et al., 2003)
and harlequin ichthyosis (OMIM
242500) (Akiyama et al., 2005; Kelsell
et al., 2005). Until now, only a few
cases of autosomal recessive congenital
Abbreviations: LI, lamellar ichthyosis; NBCIE, non-bullous congenital ichthyosiform erythroderma;
MM, malignant melanoma
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ichthyosis with ABCA12 mutations have
been reported (Akiyama et al., 2006,
2007; Thomas et al., 2006).
In this study, we have identified two
novel ABCA12 mutations in two un-
related NBCIE patients. Interestingly,
both patients presented with multiple
skin malignancies including malignant
melanoma (MM).
A 37-year-old Japanese female (pa-
tient 1) had been suffering from NBCIE
from birth and had MM on her left thigh
(Figure 1a). As complete resection and
adjuvant chemotherapy, no recurrence
of MM had been observed for 4 years.
At the age of 40, she presented with
cutaneous lymphoma on her trunk
(Figure 1c and d). Patient 2 was a 42-
year-old Japanese man with NBCIE,
who had been treated with oral reti-
noids for decades, and developed
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Figure 1. Clinical features and ABCA 12 mutations of patients 1 and 2. (a) MM developed on the posterior surface of the left thigh of patient 1 at the age of 37.
(b) MM developed on the flexor surface of the left thigh of patient 2 at the age of 47. Multiple black to brown-colored macules up to 25 mm in diameter with
irregular borders were observed. He received a wide local excision of all tumors and dissection of inguinal lymph nodes, followed by combination adjuvant
chemotherapy. No local recurrence or distant metastasis has been observed for 9 months after the operation. (c) The abdomen of patient 1 at the age of 40.
Multiple erythematous nodules were observed. Nodules were partly ulcerated (arrowheads). (d) In Patient 1, at the age of 40, small- to medium-sized atypical
lymphocytes, intermingled with a few histiocytes and eosinophils were infiltrated in the dermis of erythematous plaques (haematoxylin and eosin, bar: 5 mm).
The infiltrated cell phenotypes were CD3þ , CD4þ , CD8, CD30, CD56. The T-cell receptor beta gene rearrangement proved the monoclonal nature of the
infiltrated T cells (data not shown). Physical examination and imaging studies demonstrated no evidence of lymph node or organ involvement of lymphoma. We
diagnosed the lesion as primary cutaneous CD4þ small/medium-sized pleomorphic T-cell lymphoma according to the WHO-EORTC classification for
cutaneous lymphomas (Willemze et al., 2005). She was treated with electron beam irradiation and three cycles of cyclophosphamide, adriamycin, vincristine,
and prednisone (CHOP) chemotherapy, which lead to complete remission of lymphoma. At the age of 41, recurrence was observed in the skin and the gastric
mucosa. She received salvage chemotherapy, resulting in a partial lymphoma remission. (e) Direct sequencing of ABCA12 gene revealed a homozygous
c.1033A4C transversion in ABCA12 exon 9 in patient 1, but not in normal control samples. A heterozygous c.4481T4C transition was found in exon 30 of
ABCA12 of patient 2, but not in normal controls. Both the c.1033A4C transversion and c.4481T4C transition were novel missense mutations that changed a
threonine residue at codon 345 to a proline residue (p.Thr345Pro) and an isoleucine residue of codon 1494 to a threonine residue (p.Ile1494Thr), respectively.
(f) Schematic sequential arrangement of the domain structures of ABCA12 protein and the positions of mutations in the present two patients. Mutations in the
patients were marked by red arrows. Note that the missense mutation p.Thr345Pro was located in the cytoplasmic region between the N-terminus and the first
transmembrane domain and the other missense mutation p.Ile1494Thr was within the first adenosine triphosphate-binding cassette, which is thought to be
important for ABCA12 lipid transporter activity. (g and h) ABCA12 amino-acid sequence alignment showed the level of conservation in diverse species of the
amino-acid T345 and I1494 (red characters).
Figure 2. Ultrastructural and immunofluorescent analysis. (a and b) Abnormal lamellar granules, lipid vacuoles, and vesicles in the granular layer cells and
horny layer cells of patient 1. (a) Abnormal lipid vacuoles were seen in the keratinized cells of patient 1 (bar: 0.5 mm). (b) Large vesiculated vacuoles, putative
accumulated abnormal lamellar granules, were observed in the cytoplasm of the granular layer cell of patient 1 (bar: 0.5 mm). Abnormalities of lipid droplets in
the keratinized cells in the stratum corneum were milder than those in the skin samples from typical harlequin ichthyosis patients harboring ABCA12 truncation
mutations (Akiyama et al., 2005). (c–e) Double immunolabeling of ABCA12 and glucosylceramide in the upper epidermis. (c and d) Weak, diffuse ABCA12 (red)
staining was seen in the cytoplasm of the upper epidermal keratinocytes of patients 1 (c) and 2 (d). Glucosylceramide (green) staining was also observed in the
cytoplasm of upper epidermal keratinocytes of the patients. In some cells, glucosylceramide accumulated in the perinuclear areas (arrows). (e) In normal control
epidermis, both ABCA12 (red) and glucosylceramide (green) staining were intense in the granular layers (bar: 20 mm). These findings confirmed that the present
patients have detectable amounts of ABCA12 protein, though mutated, in the epidermis, although it could not be excluded that these abnormal findings might be
somewhat influenced by oral retinoid treatment taken by patient 2. (c) Patient 1; (d) patient 2; (e) normal control. ABCA12, red (TRITC); glucosylceramide, green
(FITC); nuclear stain, blue (TOPRO). (f and g) Altered glucosylceramide distribution in the patient’s cultured keratinocytes. (f) In normal cultured human
keratinocytes, glucosylceramide (green) was diffusely observed within the cytoplasm extending to the cell periphery. (g) In keratinocytes cultured from patient 2,
glucosylceramide (green) was seen mainly in the perinuclear area of cytoplasm, indicating abberant glucosylceramide transport. Glucosylceramide, FITC
(green); nuclear staining, propidium iodide (red). Bar¼10 mm.
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cutaneous squamous cell carcinoma on
his neck the details of which have been
described elsewhere (Arita et al., 2003).
Recurrence of squamous cell carcino-
ma has not been observed in the 5 years
since complete resection was per-
formed. At the age of 47, MM appeared
on his left thigh (Figure 1b). Neither
patient had significant family history or
apparent risk factors for carcinogenesis.
To elucidate the patients’ genetic
abnormality, blood samples were col-
lected. All the experiments, skin biop-
sies and blood sampling were
performed with the patients’ informed,
written consent and with the institu-
tional approval of Hokkaido University
Graduate School of Medicine and
Hokkaido Cancer Institute for experi-
ments handling human matter in ac-
cordance with the Declaration of
Helsinki Principles. No mutation was
found in transglutaminase 1 in either
case by direct sequencing analysis (data
not shown). Then, the ABCA12 gene
was amplified by the methods pre-
viously reported by Akiyama et al.
(2005). DNA sequencing of all the
PCR products was carried out using an
ABI PRISM 3100 genetic analyzer (ABI
Advanced Biotechnologies, Columbia,
MD). Mutational analysis of the entire
53 exons including the intron–exon
boundaries of the ABCA12 gene re-
vealed a homozygous c.1033A4C
transversion (p.Thr345Pro) in exon 9
in patient 1 and single mutation
c.4481T4C transition (p.Ile1494Thr)
in exon 30 was detected only in one
allele in patient 2 (sequence according
to Lefe`vre et al. (2003)) (GenBank
accession NM 173076) (Figure 1e and
f), although no other mutations have
been identified on the other allele thus
far. The presence of both mutations was
excluded in 200 alleles of 100 healthy
unrelated Japanese individuals. Enzyme
digestion assays and direct sequencing
of RT-PCR amplification products from
exon 30 mRNA confirmed that both
alleles with and without the mutation
c.4481T4C were expressed in the epi-
dermis of patient 2 (data not shown).
Sequencing of the entire ABCA12
mRNA from the epidermis of patient 2
did not reveal any other apparent
mutation (data not shown). These find-
ings have excluded the possibility of a
whole or partial gene deletion affecting
the other ABCA12 allele in patient 2.
ABCA12 amino-acid sequence align-
ment shows that the threonine residue
at codon 345 and the isoleucine residue
at codon 1494 are conserved among
several species (Figure 1g and h).
Electron microscopic examination of
osmium tetroxide-fixed samples from
lesional skin of patient 1 revealed that
in the cytoplasm of granular layer kera-
tinocytes, abnormal, defective lamellar
granules were assembled together with
some normal-appearing lamellar gran-
ules (Figure 2a and b). Electron micro-
scopic findings from lesional skin of
patient 2 partly showed the similar
features to those of patient 1, although
they were intensely influenced by long-
term retinoid treatment and were not
consistent in the entire specimen.
Immunofluorescence studies of pa-
tients’ skin performed as previously
described (Akiyama et al., 1999) re-
vealed that the intense ABCA12 stain-
ing seen in the granular layer cells of
normal epidermis was absent in the
both patients’ epidermis (Figure 2c–e).
Immunofluorescent staining showed
that glucosylceramide, a major lipid
component of lamellar granules
(Holleran et al., 1993; Vielhaber
et al., 2001; Ishida-Yamamoto et al.,
2004) was sparsely distributed in
the upper layers of the patients’
epidermis, compared with a more
restricted, intense distribution in
the granular layers of normal skin
(Figure 2c–e).
Culture of keratinocytes from patient
2 under high-Ca2þ conditions (2.0 mM)
induced a large number of cells to
express condensed glucosylceramide
staining around the nuclei, whereas
culture of normal human keratinocytes
under the same conditions revealed a
more diffuse staining throughout the
cytoplasm (Figure 2f and g).
Most ABCA12 mutations are known
to lead to harlequin ichthyosis or LI.
The growing number of cases leading to
three types of autosomal recessive
congenital ichthyosis (NBCIE, LI, and
harlequin ichthyosis) may be caused by
an ABCA12 functional deficiency. Gen-
erally, mild ABCA12 dysfunction
causes LI, and a serious loss of function
leads to harlequin ichthyosis. However,
only one patient with ABCA12 muta-
tions was initially reported to show a
NBCIE phenotype (Lefe`vre et al., 2003).
It is now well recognized that the
phenotypic differences existing be-
tween NBCIE and LI phenotypes are
not gene specific and can even be
found within homogeneous kindreds.
The present cases further support the
idea that an NBCIE phenotype can be
caused by ABCA12 mutations.
Skin neoplasia occurring in conge-
nital ichthyosis patients, including LI
(Elbaum et al., 1995), Netherton’s
syndrome (Weber et al., 2001; Saghari
et al., 2002; Krasagakis et al., 2003),
ichthyosis hystrix (Judge and McGib-
bon, 1994; Stratigos and Tsambaos,
1995), KID syndrome (Madariaga
et al., 1986; Grob et al., 1987; Hazen
et al., 1989; Kim et al., 2002; van
Steensel et al., 2002), and MAUIE
syndrome (Elbaum et al., 1995; Hendrix
et al., 1997), has been reported,
although we cannot find any reports
of MM and cutaneous lymphoma
associated with congenital ichthyosis
patients in the literature.
We cannot assume a direct associa-
tion of ABCA12 mutations to skin
malignancy in our patients, as ABCA12
is expressed mainly in keratinocytes,
not in melanocytes or lymphocytes
(Annilo et al., 2002; Peelman et al.,
2003; Akiyama et al., 2005). Defective
ABCA12 function is thought to result in
malformation of intercellular lipid
layers in the stratum corneum of the
patients. Owing to this lipid barrier
deficiency, the skin surface is likely to
be easily irritated, resulting in a chronic
state of inflammation. These recurrent
and long-lasting irritation and inflam-
mation processes may increase the
likelihood of skin carcinogenesis,
perhaps through promotion of tumor
progression, although the exact mecha-
nisms remain unknown.
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